New immune cell therapy targets aggressive blood cancers in kids and adults

NCT ID NCT06316427

Summary

This study is testing a new type of personalized immune cell therapy called CD7 CAR T-cells for patients with T-cell blood cancers that have returned or not responded to other treatments. The therapy involves collecting a patient's own immune cells or using donor cells, modifying them to better target cancer, and infusing them back. The main goals are to first check the safety of the treatment and then to see how well it works in controlling the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing GoBroad Hospital

    RECRUITING

    Beijing, Beijing Municipality, 102206, China

  • Shanghai Liquan Hospital

    RECRUITING

    Shanghai, Shanghai Municipality, 201418, China

  • The General Hospital of Western Theater Command PLA

    NOT_YET_RECRUITING

    Chengdu, Sichuan, 610083, China

  • Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine

    RECRUITING

    Shanghai, Shanghai Municipality, 200435, China

Conditions

Explore the condition pages connected to this study.